Subject to confirmation at today's close. AAPL will generate a Buy Signal for the Sep $190 calls. If triggered, a confirmation will go out at market open tomorrow. As for BIIB, it popped 20% in the past two days on very successful 18-month Phase II results on their novel drug for reducing the progression of Alzheimer's. Phase III results, which would be headline news for an entire generation of baby boomers, are due out later this year. Our BIIB short trade only reached +26% before this news, but the loss pales in comparison to the ramifications of these results. More on this in the weeks ahead. "The current $259 billion cost of Alzheimer’s care in the U.S. will reach an “unsupportable” $1 trillion annually by 2050, according to the Alzheimer’s Association."
